NGM Biopharmaceuticals
NGM Biopharmaceuticals: A clinical-stage company developing novel therapeutics for various diseases in the US.
NGM Biopharmaceuticals: A clinical-stage company developing novel therapeutics for various diseases in the US.
Founded in South San Francisco, NGM Biopharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics. Their mission is to translate complex biological insights into life-changing medicines with urgency and precision. NGM focuses on addressing significant unmet medical needs in cardio-metabolic, liver, oncologic, and ophthalmic diseases through a diverse pipeline of biologic drug candidates, all discovered in-house. Their vision is to make lasting scientific contributions that improve human life.
NGM Biopharmaceuticals has attracted notable investors and industry leaders, contributing to its robust development pipeline. The company has achieved significant milestones in clinical trials, advancing several promising drug candidates. Their innovative approach and commitment to addressing critical health issues have positioned them as a key player in the biopharmaceutical industry, making a substantial impact on the medical community and patients' lives.
Companies similar to NGM Biopharmaceuticals include Nimbus Therapeutics, Angion, NanoPharmaceuticals and Armetheon.
NGM Biopharmaceuticals was founded in 2007.
NGM Biopharmaceuticals' headquarters is located in South San Francisco, CA, US.
NGM Biopharmaceuticals' most recent funding round was for $125M (USD) in January 2021.
As of Jan 6, 2021, NGM Biopharmaceuticals has disclosed funding of $420.4M (USD). Undisclosed round amounts are excluded.
NGM Biopharmaceuticals has 225 employees as of Feb 6, 2024.
Armetheon
